Proteins linked to type II interferon response in Sjogren's disease: novel indicators for disease monitoring and predicting treatment response to leflunomide and hydroxychloroquine combination therapy.

ABSTRACT:

Objective

To identify biomarkers and endotypes predictive of treatment response, monitor disease activity, and explore pathways associated with the clinical efficacy of leflunomide and hydroxychloroquine combination therapy (LEF/HCQ) in patients with primary Sjögren's disease (SjD).

Methods

Serum proteome (Olink Immuno-oncology panel, analyzing 92 proteins) of 29 patients with SjD of the RepurpSS-I study and 8 healthy controls was analyzed at baseline and after 24 weeks of LEF/HCQ. Proteomic changes were correlated to standard and novel clinical endpoints. Transcriptome data of blood mononuclear cells and monocytes were used to assess type I and II IFN scores.

Results

At baseline, 29 proteins were differentially expressed between SjD and HC. LEF/HCQ significantly down

SUBMITTER: Wong WY 

PROVIDER: S-EPMC12575357 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature